Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT07012759
Recruiting Observational

Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients

NCT07012759 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Fu Jen Catholic University
Phase
Observational
Started
2025-06-10
Last updated
2026-03-05

Condition(s) studied

BiomarkersLung AdenocarcinomaPleural Effusion

Investigational drug(s) / intervention(s)

biomarkers

biomarkers: pleural effusion biomarkers in lung adenocarcinoma

Study summary

This project aims to assess the expression levels of novel molecular markers identified through screening in clinical samples of malignant pleural effusion, to evaluate the feasibility and clinical utility of these markers as potential diagnostic genes for lung adenocarcinoma.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients requiring thoracentesis for pleural effusion drainage as determined by a physician based on clinical need. * Signed informed consent. Exclusion Criteria: * Patients under the age of 18. * Patients with malignancies other than lung adenocarcinoma.

Primary outcome measure(s)

  • target gene expression levels between malignant and non-malignant pleural effusions — 20 minutes
    Novel biomarkers specifically expressed in malignant pleural effusions may provide additional diagnostic options for malignant lung cancer in clinical diagnosis

Trial sites (1)

FacilityCityRegionStatus
Fu Jen Catholic University Hospital, Fu Jen Catholic University New Taipei City Taiwan Recruiting

More Fu Jen Catholic University trials in Taiwan

Regional Innovation in Chronic Disease and Elderly Care Recruiting
Probiotics in Pulmonaty Rehabilitation for COPD Recruiting
Pressure-Sensing Mattresses and Mechanical Ventilation Weaning in Neonatal Recruiting
Association Between Cardiopulmonary Function and Plantar Pressure in Patients With Chronic Obstructive Pulmonary Disease Recruiting
Development of a Multimodal Deep Learning Model for Pediatric Patients Recruiting

Other trials for the same condition

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07012759 on ClinicalTrials.gov ↗ ← All trials in Taiwan